Tower Research Capital (TRC)’s Windtree Therapeutics WINT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
– Sell
-664
Closed -$1K – 4535
2016
Q4
$1K Buy
664
+244
+58% +$451 ﹤0.01% 3743
2016
Q3
$1K Sell
420
-30
-7% -$65 ﹤0.01% 3495
2016
Q2
$1K Sell
450
-2,047
-82% -$4.95K ﹤0.01% 4323
2016
Q1
$4K Buy
2,497
+2,211
+773% +$4.75K ﹤0.01% 2999
2015
Q4
$1K Buy
+286
New +$1.17K ﹤0.01% 4303
2015
Q1
– Sell
-49
Closed -$1K – 5298
2014
Q4
$1K Buy
49
+18
+58% +$396 ﹤0.01% 3842
2014
Q3
$1K Sell
31
-178
-85% -$4.3K ﹤0.01% 4255
2014
Q2
$5K Buy
+209
New +$5.34K ﹤0.01% 2919
2013
Q4
– Sell
-156
Closed -$4K – 5218
2013
Q3
$4K Sell
156
-660
-81% -$16K ﹤0.01% 3864
2013
Q2
$17K Buy
+816
New +$20.1K ﹤0.01% 1898

Other funds holding WINT

Tower Research Capital (TRC)'s WINT Position: Q1 2017 in Review

Tower Research Capital (TRC) sold out of Windtree Therapeutics (WINT) in Q1 2017, closing a stake of 664 shares — an estimated $1K sold.

Tower Research Capital (TRC) first reported a position in WINT in Q2 2013 and held it in 10 quarters. The position peaked at $17K in Q2 2013. 26 funds tracked by Wall St. Rank hold WINT as of Q1 2017.

  • Tower Research Capital (TRC) reported no remaining Windtree Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 664 Windtree Therapeutics shares in Q1 2017, an estimated $1K.
  • Tower Research Capital (TRC) first reported a position in Windtree Therapeutics in Q2 2013 and held it in 10 quarters.
  • Tower Research Capital (TRC)'s Windtree Therapeutics position peaked at $17K in Q2 2013.
  • 26 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2017, filed 19 May 2017.